source
- Novartis' radioligand therapy Lutathera could soon face generic competitionThe radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...Endpoints · 3mo ago↗ source
- Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campusThe 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.BioPharma Dive · 3mo ago↗ source
- Roche, facing biosimilar threats, puts faith in new cancer and obesity drugsOn a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.